Helix, a leading enterprise genomics company, has announced a multi-year relationship with AstraZeneca, a global biopharmaceutical company. Under this agreement AstraZeneca will gain access to Helix’s continuously growing, deeply phenotyped GenoSphere cohorts that cover a wide range of disease areas.
GenoSphere cohorts consist of comprehensive Exome+ genomic and rich longitudinal clinical data, designed to accelerate Life Sciences research across the development cycle. These de-identified datasets are powered by the Helix Research Network, the largest and fastest growing precision health network in North America.
Key advantages of Helix’s datasets and network:
- Genomic data from Exome+ sequencing provides deep insights into thousands of genes and variants across a range of disease areas including cardiometabolic, respiratory, autoimmune and more.
- Curated, longitudinal clinical data with an average electronic health record (EHR) history of 13 years that includes diagnoses, lab results, and more with regular data refreshes to follow the patient journey.
- Fully consented cohort to launch targeted follow-on studies with speed and precision.
